Main Content
All the Rest
PulmCrit – Preliminary report on NIAID trial of remdesivir (ACTT-1)
The preliminary report of the Adaptive COVID-19 Treatment Trial (ACTT-1), a multi-center, placebo-controlled RCT on remdesivir is here!1 The one we’ve all been waiting for! Patients Patients were recruited from 60 sites in several countries. Inclusion criteria were patients who were hospitalized due to COVID-19 with evidence of lower respiratory tract infection, defined in terms […]
PulmCrit – Sodium Zirconium Cyclosilicate for urgent treatment of hyperkalemia?
Sodium Zirconium Cyclosilicate (SZC) is a potassium-exchange resin similar in concept to sodium polystyrene sulfonate (Kayexalate). It’s not particularly new, as the original studies were performed around 2015. Accumulating evidence over the last five years supports the drug’s safety. The real question is how effective it may be. Efficacy data for short-term improvement in potassium […]
IBCC chapter & cast – COPD exacerbation
COPD exacerbation is bread and butter critical care. However, familiarity can breed concept. Thus, it’s important to always approach patients labeled with “COPD exacerbation” with fresh eyes, because they can present with other pulmonary pathologies as well. The primary challenge among these patients is usually utilizing noninvasive support devices to avoid intubation, whenever possible. The […]
EMCrit Wee – A Theoretical Model of the Pathophysiology of COVID-19 with Farid Jalali (Not a Single Thing Verified–Pure Musings)
Today on the podcast, my guest lays out a theoretical framework for the pathophysiology of the lung effects of COVID-19.
- 1
- 2
- 3
- …
- 242
- Next Page »